Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

News Features

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

Shelley Wood

December 20, 2022

News Daily News

AI Accurately Detects LV Dysfunction Using Single-Lead Apple Watch ECG

Todd Neale

November 17, 2022

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

Presentation TCT 2022

TCT 681: Alcohol Septal Ablation for Preoperative Optimization Prior to Noncardiac Surgery in Hypertrophic Cardiomyopathy

Presenter: Sina Salehi Omran

September 18, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Conference News ESC 2022

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

Shelley Wood

August 27, 2022

News Daily News

OHCA in Pregnancy: Extremely Rare, Often Deadly

Caitlin E. Cox

August 24, 2022

News Daily News

Antibiotics Before Invasive Dental Work Helpful in High-Risk Patients

Caitlin E. Cox

August 22, 2022

Presentation TVT 2022

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Presenter: David Hsi

June 09, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2022

Shelley Wood

May 02, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ACC 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presenter: Florian Rader

April 04, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Conference News ACC 2022

What’s Going to Be Hot at ACC 2022, In Person or Virtual

Shelley Wood

March 28, 2022

News Daily News

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Yael L. Maxwell

February 24, 2022

Advertisement

Heart Failure Care Has a Pipeline Problem: What’s the Fix?

AI Accurately Detects LV Dysfunction Using Single-Lead Apple Watch ECG

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

TCT 681: Alcohol Septal Ablation for Preoperative Optimization Prior to Noncardiac Surgery in Hypertrophic Cardiomyopathy

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

EchoNet AI Algorithm Beats Sonographers for Estimating LV Function

OHCA in Pregnancy: Extremely Rare, Often Deadly

Antibiotics Before Invasive Dental Work Helpful in High-Risk Patients

Percutaneous Intramyocardial Septal Radiofrequency Ablation (PIMSRA) for Hypertrophic Obstructive Cardiomyopathy: Results From the First 200 Patients

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

TCTMD’s Top 10 Most Popular Stories for April 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

What’s Going to Be Hot at ACC 2022, In Person or Virtual

AI-Based Tool IDs Hypertrophic Cardiomyopathy and Cardiac Amyloidosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content